The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Insights into the Phase III CERVINO trial: ABBV-383 for R/R myeloma
In this video, Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, shares insights into the Phase III CERVINO trial (NCT06158841), which is evaluating the safety of ABBV-383 (etentamig), a novel BCMA-directed bispecific T-cell engager, in patients with relapsed/refractory multiple myeloma (R/R MM). This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
